The pharmacokinetics of oxybutynin in man

  title={The pharmacokinetics of oxybutynin in man},
  author={Jacques Douchamps and F. Derenne and Armel Stockis and Diamon Gangji and M. Juvent and Andr{\'e} Herchuelz},
  journal={European Journal of Clinical Pharmacology},
SummaryWe have studied the pharmacokinetics of oxybutynin (Ditropan) after single oral (5 mg) and intravenous administration (1 and 5 mg), and after repeated oral administration in healthy volunteers.Oxybutynin was rapidly absorbed, maximum plasma concentrations (8 ng·ml−1) being reached in less than 1 h. The absolute systemic availability averaged 6% and the tablet and solution forms displayed similar relative systemic availability.Plasma concentrations of oxybutynin fell biexponentially, the… 

Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin

The succinate salt of solifenacin, a tertiary amine with anticholinergic properties, is used for symptomatic treatment of overactive bladder and appears to have better tolerability than immediate-release (IR) oxybutynin 10–15 mg/day and IR tolterodine 4 mg/ day.

Pharmacokinetics and Metabolism of Transdermal Oxybutynin: In Vitro and in Vivo Performance of a Novel Delivery System

Sustained delivery over 4 days and multiple sites allow a convenient, well-tolerated, twice-weekly OXY TDS dosing and the consistent delivery, absorption, and pharmacokinetics should result in an effective treatment of patients with overactive bladder.

Plasma levels of oxybutynine chloride in children

The results of the study argue against the dosage regimen proposed before these adverse events were detected, and strongly favour a dose adapted to the body weight of the child, with a 12-hour interval between doses.

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.

Lower N-desethyloxybutynin plasma concentration and greater saliva output during transdermal treatment correspond to the reported low incidence of dry mouth in patients with overactive bladder and minimizes metabolism to N- Desethyloxy butynin compared with extended-release oral administration.

Pharmacokinetics of the R- and S-Enantiomers of Oxybutynin and N-Desethyloxybutynin Following Oral and Transdermal Administration of the Racemate in Healthy Volunteers

The differences between R-OXY and R-DEO following the two routes of administration support the potential for comparable clinical efficacy and reduced anticholinergic side-effects with transdermal treatment.

Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo

Data indicate that for the stereoselectivity of OXY, the unbound fraction of each OXY enantiomer was a major factor and the metabolism in liver had a minimal effect.

Oxybutynin Extended-Release

Oxybutynin ER shows excellent efficacy in the treatment of symptoms associated with OAB in adults and the elderly with a good tolerability profile over a prolonged period of use (12 months), and provides an excellent treatment option in the first-line pharmacotherapy of OAB.

Pharmacokinetics of Oxybutynin Chloride Topical Gel

The bioavailability of oxybutynin and its pharmacokinetic profile are not greatly affected by application site selection, post-application showering or sunscreen use shortly before or after dosing with OTG.

The action of oxybutynin on haemodynamics and metabolism in the perfused rat liver.

Apparently, upon administration of oxybutynin, a considerable fraction of the liver parenchyma ceased to be irrigated or almost so, which is apparent from the concomitant inhibition of oxygen uptake, pressure increase and inhibition of glucose, lactate and pyruvate release together with the simultaneous intracellular accumulation of glucose and glucose 6-phosphate.



Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay.

The antimuscarinic activity of oxy butynin was measured as oxybutynin equivalents by a radioreceptor assay (RRA) and its metabolites are measured by RRA, but only the parent drug by GLC.

Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

A mathematical equation is presented which enables one to determine the parameters identical to an i.v. bolus injection curve by utilizing the postinfusion blood curve, applicable to all compartmental models that may be described by linear first-order differential equations with constant coefficients.

Pharmacogenetics of Tolbutamide Metabolism in Humans

Evidence is provided for monogenic control of tolbutamide metabolism in man and the results suggest that fixed dosage regimens of this drug, as were prescribed in the controversial University Group Diabetes Program study, might lead to higher accrued blood levels in slow inactivators.

A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan) on rabbit detrusor.

Oxybutynin possesses a notable antispasmodic activity distinct from its anticholinergic activity and stronger than that of atropine, propant heline, or methantheline, which may prove useful in the treatment of smooth muscle hypermotility.

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

The co-inheritance of extensive and poor hydroxylation of mephenytoin and nirvanol, respectively, represents a new drug hydroxymation polymorphism in man.

Symmetrical confidence intervals for bioequivalence trials.

This modification has the effect of decreasing the "effective" length of the confidence interval, on which the decision concerning bioequivalence is based, while increasing the confidence coefficient.

Oxybutynin--a musculotropic antispasmodic drug with moderate anticholinergic action.